Benign and premalignant disease of the cervix

Dr Sushma Sharma


Introduction

- Benign diseases of the cervix are common and are unusually asymptomatic or cause minor symptoms but must be differentiated from malignancy.
- Cervical cancer is the second commonest cancer in women. It is proceeded by a premalignant form years before its invasion.
- Screening for premalignant disease of the cervix markedly reduces the deaths from cervical cancer.

objective

- To understand the normal cervical epithelium
- To be able to define metaplasia and dysplasia.
- To understand the concept of cervical screening.
- To outline the principles of colposcopy.
- To outline the management of CIN


Epithelium of the cervix





THE CERVICAL TRANSFORMATION ZONE

The cervical transformation zone extends from the endocervical margin of the original squamous epithelium of the ectocervix to the identified squamo-columnar junction.

Over 95% of all cervical intraepithelial neoplasias (CIN) arise within the transformation zone of the cervix.







HPV infection

- DNA virus.
- Over 100 different types and subtypes of this virus.
- Common infection effecting epithelial surface.
- Genital HPV is divided into
- ≻ Low risk type (HPV 6,11) cause genital warts.
- ≻ High risk types (HPV **16**, **18**, 31, 33, 45, 56).
- HPV is a common infection while cervical cancer is a rare disease.

HPV is Epitheliotropic

- No viremia
- Infection is confined to where it initiated
- Spreads by infected cell dividing.

Factors that increase risk of transmission:


- Smoking.
- Increasing parity.
- Early age of intercourse.
- Oral contraceptive pills.
- Immunity.

Cervical intraepithelial neoplasia

- Metaplasia: change of epithelium from one cell lining (columnar) to another (squamous).
- Dysplasia: abnormal epithelial cells that fail to maturate. (hyperchromasia, larger, variable size, mitosis).
 it may be mild, moderate or severe

Cervical Dysplasia: Classification

Normal Cervix




Images from: www.mibovo.com/women/dysplasia.htm


Cervical Dysplasia: Classification

Cervical Intraepithelial Neoplasia (CIN 1)

Mild Dysplasia




Cervical Intraepithelial Neoplasia (CIN 2)




Images from: www.mibovo.com/women/dysplasia.htm

Cervical Dysplasia: Classification

Cervical Intraepithelial Neoplasia (CIN 3)




Invasive Cervical Cancer (ICC)



Images from: www.mibovo.com/women/dysplasia.htm

Classification of CIN



CERVICAL INTRAEPITHELIAL NEOPLASIA (CIN): Mild Dysplasia / CIN 1: Dysplasia confined to the lowest third of the epithelium.

Moderate Dysplasia / CIN 2: Dysplasia involving the lower two thirds of the epithelium.

Severe Dysplasia / CIN 3: Dysplasia extending into the upper third of the epithelium, but not involving the full thickness.

Carcinoma In Situ / CIN 3: A squamous intraepithelial lesion in which nuclear abnormalities involve the full thickness of the epithelium.

Bethesda 2001 Cervical Cytology Classification Negative for squamous intraepithelial lesion or malignancy

Epithelial cell abnormalities: Squamous Cell

Atypical Squamous cells of undetermined significance (ASC-US)

Atypical Squamous Cells, cannot exclude HSIL (ASC-H)

Low-Grade Squamous Intraepithelial Lesion (LSIL) encompassing: HPV / mild dysplasia / CIN 1 High-Grade Squamous Intraepithelial Lesion (HSIL) encompassing: moderate and severe dysplasia, CIS / CIN 2 &

CIN 3

-with features suspicious for invasion (if invasion is

suspected)

Sauamana call agrainama

The Bethesda 2001 System


Major New Changes from Bethesda 1991:

- * Negative for intraepithelial lesion or malignancy replaces "within normal limits".
- *Benign Cellular Changes Eliminated.
- *ASCUS changed to ASC : either ASC-US or ASC-H
- *AGUS changed to AGS

COMPARISON OF THE WHO AND BETHESDA SYSTEM TERMINOLOGY

WHO histopathologic terms Bethesda Cytology Ter CIN 1/ Mild Dysplasia LSIL **HSIL** CIN 2 / Moderate Dysplasia **CIN 3 / Severe Dysplasia HSIL** CIN 3 / Carcinoma in Situ **HSIL** *LSIL: low-grade squamous intraepithelial lesion *HSIL: high-grade squamous intraepithelial lesion

Cervical Cancer



Gross pathology of Cervix

Micro pathology of Cervix

Normal, Ectopic and Cancerous Cervices



Seattle STD/HIV Prevention Training Center

Source: Claire E. Stevens



Seattle ST0/GIV Prevention Training Center

Source: Claire E Stevens



Slide courtesy of ITECH

Outcome of CIN


- > Spontaneous regression.
- Progression to invasive cancer.
- Progression from one stage to another takes years.
- Detection and treatment of CIN prevents cancer cervix.

Natural history of CIN: summary


		Progress Progress		
	Regress	Persist	to CIS	to invasion
CIN 1	57%	32%	11%	1%
CIN 2	43%	35%	22%	5%
CIN 3	32%	< 56%		>12%

64 studies, 274 carcinomas, 15,473 CIN cases Followup <1-12 years

Östör AG, Int J Gyne Path 1993;12:186-192




Progression



Melnikow J et al. Obstet Gyne 1998;92:727-35

Invasive Cancer




Melnikow J et al. Obstet Gyne 1998;92:727-35

Cervical Cancer: Risk Factors

- Early onset of sexual activity
- Multiple sexual partners
- High-risk sexual partner history of sexually transmitted diseases
- Smoking
- High parity
- Immunosuppression
- Low socioeconomic status
- Prolonged use of oral contraceptives
- Previous history of vulvar or vaginal squamous dysplasia

Screening for CIN cervical smear

- Screening for dyskariosis by obtaining cervical cytology.
- Cervical screening should be carried out every 3-5 years in all sexually active women from 20-60 years of age.
- There is a 10-15 % chance of false positive or false negative results.



www.similima.com

Colposcopy

- Is the inspection of the cervix with a low powered microscope.
- Magnifies the cervix 4-20 times.
- The patient is put in lithotomy position.
- Passing a bivalve speculum gently into the vagina.


- Inspection of the cervix and its vasculature.
- Green filter may help studying vasculature.
- Abnormal vascular structure includes punctuation and mosaicism.
- Acetic acid test: application of 3% acetic acid stained the abnormal area. The degree of staining correlates with severity of the lesion.
- Schiller test: application of Lugol's iodine stains the normal cervix brown.
- Colposcopy gives a clinical diagnosis.
- Punch biopsy from the abnormal area gives a histopathological diagnosis.

Colposcopy

- Accurate delineation of suspicious areas for tissue biopsy.
- Suspicious areas appear as acetowhite areas.

Indications

- Abnormal papsmear cytology.
- ✓ To locate abnormal areas.
- To obtain directed biopsy.




t/t of dysplasia & cin

- Mild dysplasia : Treat inflammation & advise follow up pap test every 3 to6 months
- Moderately severe to severe dysplasia/CIN II,III
 - 1. Local destructive
 - a. Cryosurgery
 - b. Fulguration
 - c. Laser ablation
 - d. Cauterisation
 - 2. Excision of abnormal tissue :
 - a. Cold knife conization
 - b. Laser conization
 - c. LLETZ /laser large loop excision of the transformation zone
 - 3. <u>Surgery</u>
 - a. Hysterectomy
 - b. Therapeutic conization

www.similima.com

Tissue biopsy



MANAGEMENT OF CIN 1

Risk of follow up of CIN 1 -

1. Invasive cancer already exists and was missed by Pap, colpo and biopsy.

Invasive cancer develops between follow up visits.

3. Patient lost to follow up and develops invasive cancer.

FOLLOW UP FOR CIN 1 Atypia / LSIL Pap

Follow up 24 mo 135 pts. Immediate LLETZ 171 pts.

Histology

20%	Negative	< 1 %
55%	CIN 1/HPV	76%
24%	CIN 2-3	23%
l pt.	Invasion	

Shafi, BJOJ, 1997

FOLLOW-UP: OBSERVATION VS. THERAPY

Patients with Pap smears interpreted as LSIL may have colposcopy directly if reliable and have the ability to be followed, may be followed by repeat smears at 4 to 6 months.

A meta-analysis of women with LSIL Pap tests had a pooled rate of regression reported as 47.39%, with a very low

risk of invasive carcinoma, varying from 0.00% to

0.74% of the patients.

OBSERVATIONAL FOLLOW-UP, CIN 1 If the patient has a follow-up Pap smear that is within normal, or benign cellular changes, repeat follow-up at 4 to 6 month intervals should continue. If the smears remain within normal, or benign cellular changes, the patient may return to annual yearly screening if

METHODS TO TREAT CIN

There are a variety of accepted methods of therapy to treat CIN, including: cryosurgery ablation, laser ablation or excision, electro-loop excision, cone biopsy

ACOG: 1997; Nuovo et al, 2000; Wright et al, 1995

Management of abnormal colposcopy

- CIN II, CIN III. ?CIN I.
- Techniques for treatment:

Excisional: LLETZ, laser cone, knife cone, hysterectomy.


- *Ablative:* radical electrodiathermy, cold coagulation, cryocautery, laser.
- 90-95% cure rate







BEFORE SURGERY





IN SURGERY

HPV vaccine

- In 2006, an HPV vaccine against HPV16 and HPV18 (types most commonly responsible for cervical cancers) and HPV6 and HPV11 (cause most anogenital warts) was licensed for use in females 9-26 years old.
- The vaccine appears to be highly efficacious in preventing HPV infection and high-grade CIN in HIV negative women.
- No specific data in HIV+ women is available to date.
- The vaccine is available in Vietnam but use is limited due to the high cost.

Summary

- Benign diseases of cervix are harmless but malignancy should be excluded.
- Cervical intraepithelial neoplasia proceedes cancer cervix by years.
- Screening for CIN reduces mortality from cancer cervix.
- Those with positive screening test should be referred to colposcopy for diagnosis and treatment.

Thank You

Questions?